| Doptelet (avatrombopag) / SOBI |
| Not yet recruiting | 4 | 20 | NA | Doptelet Pill | Hvidovre University Hospital | Thrombocytopenia; Drugs, Cirrhosis, Liver, Procedural Bleeding | 06/22 | 06/22 | | |
ChiCTR2100050045: A Study to Assess the Safety and Efficacy of Avatrombopag in Chinese Patients with Aplastic Anemia |
|
|
| Not yet recruiting | 4 | 60 | | Avatrombopag treatment | Tianjin Medical University, General Hospitial; Tianjin Medical University General Hospitial, self-raised | aplastic anemia | | | | |
EAST, NCT04906083: Avatrombopag in Patients With End-stage Liver Disease and Thrombocytopenia |
|
|
| Recruiting | 4 | 150 | RoW | Avatrombopag, Standard medical treatment, transmetil, compound glycyrrhizinate, reduced glutathione and hepatocyte growth factor, et. al. | Tongji Hospital, Anhui Provincial Hospital, The First Affiliated Hospital of Nanchang University, Taihe Hospital, Hubei University of Medicine, The First Hospital of Jilin University | Liver Failure, Thrombocytopenia, Decompensated Cirrhosis | 12/22 | 12/22 | | |
NCT04915287: Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective Procedure |
|
|
| Recruiting | 4 | 476 | RoW | Avatrombopag maleate, Doptelet, Platelet transfusion, Medicine, Other drugs | Chinese PLA General Hospital | Thrombocytopenia; Drugs, Chronic Liver Disease | 06/23 | 07/23 | | |
ChiCTR2200065912: Efficacy and safety of avatrombopag in immune/targeted/antiangiogenic hepatocellular carcinoma patients with thrombocytopenia |
|
|
| Recruiting | 4 | 76 | | Avatrombopag was administered orally | Fuyang Second People's Hospital; Fuyang Second People's Hospital, Self-funded | Hepatoma | | | | |
NCT04638829: Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim |
|
|
| Completed | 4 | 60 | US | Avatrombopag Oral Tablet, Doptelet | Sobi, Inc. | Immune Thrombocytopenia | 01/24 | 01/24 | | |
NCT05382013: Efficacy and Safety of Avatrombopag for Treating TCP in HBV-ACLF Patients Receiving ALSS Treatment |
|
|
| Recruiting | 4 | 60 | RoW | Avatrombopag, Artificial Liver Support System, Comprehensive internal medical treatment. | Third Affiliated Hospital, Sun Yat-Sen University | Thrombocytopenia, Hepatitis B, Chronic, Acute-On-Chronic Liver Failure | 02/24 | 04/24 | | |
ChiCTR2200057674: Clinical study of Avatrombopag combined with immunosuppressive therapy in the treatment of severe hepatitis-related aplastic anemia in children |
|
|
| Not yet recruiting | 4 | 10 | | Avatrombopag | Capital Medical University, National Center for Children’s Health; Capital Medical University, National Center for Children’s Health, Self-financing | Severe hepatitis-associated aplastic anaemia in children | | | | |
NCT05996393: CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly |
|
|
| Not yet recruiting | 4 | 60 | RoW | Ciclosporin, Avatrombopag, Anti-Human Thymocyte Immunoglobulin, Rabbit | Peking Union Medical College Hospital | Aplastic Anemia | 10/25 | 10/26 | | |
NCT03471078 / 2018-000023-13: Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers |
|
|
| Completed | 3 | 122 | Europe, US, RoW | Avatrombopag, Placebo Oral Tablet | Sobi, Inc. | Chemotherapy-induced Thrombocytopenia | 08/20 | 01/23 | | |
| Active, not recruiting | 3 | 75 | Europe, US, RoW | Avatrombopag, Doptelet, Placebo | Sobi, Inc. | Immune Thrombocytopenia | 11/23 | 11/25 | | |
NCT05369208: Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults with Chronic ITP |
|
|
| Active, not recruiting | 3 | 19 | Japan | Avatrombopag Oral Tablet, Doptelet | Sobi, Inc. | Immune Thrombocytopenia | 01/24 | 08/25 | | |
NCT05907499: Decitabine for Poor Graft Function Post Allo-HSCT |
|
|
| Not yet recruiting | 3 | 76 | NA | Decitabine, Dec, Granulocyte Colony-Stimulating Factor, G-CSF, Thrombopoietin Receptor Agonist, Eltrombopag / Avatrombopag, Recombinant human erythropoietin, EPO | The First Affiliated Hospital of Soochow University | Poor Graft Function | 07/26 | 11/26 | | |
| Not yet recruiting | 2/3 | 40 | RoW | Avatrombopag 20 MG | Peking Union Medical College Hospital | Aplastic Anemia, Drug Effect | 12/22 | 06/23 | | |
| Not yet recruiting | 2/3 | 142 | RoW | avatrombopag, Doptelet, Placebo | Peking University People's Hospital, Xiangya Hospital of Central South University, Sichuan Provincial People's Hospital, First Affiliated Hospital of Harbin Medical University, The First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Xinjiang Medical University, Shanxi Bethune Hospital, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Tang-Du Hospital, The First Affiliated Hospital of Nanchang University | Thrombocytopenia, Stem Cell Transplant Complications | 10/24 | 10/25 | | |
NCT04896528: Efficacy and Safety of Avatrombopag in Cancer Patients With Thrombocytopenia |
|
|
| Recruiting | 2 | 30 | RoW | Avatrombopag | Peking Union Medical College Hospital | Thrombocytopenia, Avatrombopag | 12/21 | 12/21 | | |
NCT05143892: Avatrombopag to Promote Platelet Engraftment After Allo-HSCT |
|
|
| Recruiting | 2 | 20 | RoW | Avatrombopag, Doptelet, Supportive care, support | The First Affiliated Hospital of Soochow University | Platelet Disorder | 12/22 | 11/23 | | |
NCT04797182: Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma |
|
|
| Not yet recruiting | 2 | 46 | RoW | avatrombopag | Sun Yat-sen University | Thrombocytopenia, Cytarabine Causing Adverse Effects in Therapeutic Use, Lymphoma | 04/23 | 07/23 | | |
ACTRN12619001042134: Avatrombopag in untreated severe aplastic anaemia - a Bayesian optimal phase 2 study |
|
|
| Active, not recruiting | 2 | 55 | | | Monash University, Medical Research Future Fund | Newly diagnosed severe aplastic anaemia | | | | |
ACTRN12619001043123: Avatrombopag in Relapsed or Refractory Severe Aplastic Anaemia – a Bayesian Optimal Phase II study |
|
|
| Active, not recruiting | 2 | 55 | | | Monash University, Medical Research Future Fund | Refractory/relapsed severe aplastic anaemia | | | | |
NCT05720234: Avatrombopag Combined With IST as First-line Treatment for SAA |
|
|
| Recruiting | 2 | 53 | RoW | avatrombopag, AVA, APAG | Institute of Hematology & Blood Diseases Hospital | Severe Aplastic Anemia | 11/23 | 11/24 | | |
SKX-AA-001, NCT06254287: Efficacy and Safety of Avatrombopag vs. Avatrombopag Combined With rhTPO in the Treatment of SAA |
|
|
| Not yet recruiting | 2 | 60 | NA | Avatrombopag, Avatrombopag +rhTPO | Institute of Hematology & Blood Diseases Hospital, China, Fosun Pharmaceutical Distribution Jiangsu co., Limited | Anemia, Aplastic | 12/24 | 12/24 | | |
NCT06281327: Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia |
|
|
| Recruiting | 2 | 60 | RoW | Avatrombopag | Institute of Hematology & Blood Diseases Hospital, China, Henan Cancer Hospital, Tianjin Medical University Second Hospital, Tianjin Children's Hospital, The Second Affiliated Hospital of Kunming Medical University | Immune Thrombocytopenia, Treatment | 12/25 | 12/25 | | |
NCT05218226: Avatrombopag for Chemotherapy-induced Thrombocytopenia |
|
|
| Recruiting | 2 | 50 | RoW | Avatrombopag | Institute of Hematology & Blood Diseases Hospital, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University Second Hospital, Tianjin Third Central Hospital, Tianjin People's Hospital, Henan Cancer Hospital, The Second Affiliated Hospital of Kunming Medical University | Chemotherapy-induced Thrombocytopenia, Avatrombopag | 03/24 | 12/24 | | |
NCT04993885: Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies |
|
|
| Recruiting | 2 | 52 | RoW | Avatrombopag | Institute of Hematology & Blood Diseases Hospital, China | Immune Thrombocytopenia, Autoantibodies, Evan Syndrome, Connective Tissue Diseases | 07/24 | 09/24 | | |
NCT06004752: Efficacy and Safety of CsA+AVA in the Treatment of NSAA in the Elderly |
|
|
| Recruiting | 2 | 30 | RoW | Ciclosporin, Avatrombopag | Peking Union Medical College Hospital | Aplastic Anemia | 08/24 | 08/25 | | |
NCT06001567: Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC |
|
|
| Recruiting | 2 | 30 | RoW | Avatrombopag | Second Affiliated Hospital of Guangzhou Medical University | Thrombocytopenia, Hepatocellular Carcinoma | 08/24 | 08/24 | | |
| Recruiting | 2 | 40 | RoW | Avatrombopag | Anhui Provincial Hospital | Platelet Recovery After Umbilical Cord Blood Transplantation | 01/25 | 02/25 | | |
| Recruiting | 2 | 60 | US | Avatrombopag, Doptelet, avatrombopag maleate, Matching Placebo | Hanny Al-Samkari, MD, Swedish Orphan Biovitrum | Gastrointestinal Cancer, Gastrointestinal Neoplasms, Chemotherapy-Induced Thrombocytopenia | 03/25 | 07/25 | | |
| Recruiting | 1 | 24 | US | Avatrombopag | University of Rochester | Thrombocytopenia | 09/24 | 09/24 | | |
ChiCTR2100050078: A randomized controlled trial of Avatrombopag combined with traditional Chinese medicine Shengxueyin and selenium yeast in the prevention of tumor chemotherapy-induced thrombocytopenia |
|
|
| Recruiting | N/A | 120 | | Avatrombopag ;Shengxueyin and selenium yeas ;Avatrombopag with Shengxueyin and selenium yeas ;None | Huoshan County Hospital; Huoshan County Hospital, self-funded | Chemotherapy Induced Thrombocytopeniarapy | | | | |
ChiCTR2100049262: A single-arm, single-center, prospective study of avatropapa in the treatment of secondary thrombocytopenia after allogeneic hematopoietic stem cell transplantation |
|
|
| Not yet recruiting | N/A | 20 | | Avatrombopag Maleate | The Third Xiangya Hospital of Central South University; The Third Xiangya Hospital of Central South University, Jiangsu Fosun Pharmaceutical Sales Co. Ltd. | Hematologic malignancy | | | | |
ChiCTR2200061853: A prospective, single-arm, exploratory study of avatrombopag in the treatment of thrombocytopenia with TPO or TPORA ineffective |
|
|
| Not yet recruiting | N/A | 20 | | Avatrombopag | The Forth Affiliated Hospital Zhejiang University School of Medicine; The Forth Affiliated Hospital Zhejiang University School of Medicine, scientific research funds | thrombocytopenia with TPO or other TPORA ineffective | | | | |
NCT05571332: Efficacy and Safety of Avatrombopag Combined With IST for the Treatment of HAAA and SAA With Abnormal Liver Function |
|
|
| Recruiting | N/A | 39 | RoW | Avatrombopag 20 MG Oral Tablet, porcine ATG, Cyclosporine(CsA) | Institute of Hematology & Blood Diseases Hospital | Aplastic Anemia | 12/23 | 06/24 | | |
SAA, NCT05433922: Efficacy and Safety of CSA and Avatrombopag for the Treatment of in the Elderly |
|
|
| Recruiting | N/A | 80 | RoW | Avatrombopag, CSA | Institute of Hematology & Blood Diseases Hospital | Severe Aplastic Anemia | 12/23 | 12/24 | | |
ChiCTR2300069466: Analysis of the efficacy of avatrombopag in treating refractory platelet transfusion refractoriness |
|
|
| Not yet recruiting | N/A | 100 | | none | Nanfang Hospital of Southern Medical University; Nanfang Hospital of Southern Medical University, none | hematological disease | | | | |
ChiCTR2100050646: The novel effect of avatrombopag in the management of refractory chemotherapy induced thrombocytopenia (CIT) in patients with solid tumors: a single arm study |
|
|
| Recruiting | N/A | 20 | | avatrombopag | Zhejiang Provincial Hospital of Traditional Chinese Medicine; Zhejiang Provincial Hospital of Traditional Chinese Medicine, Self-funded | refractory chemotherapy induced thrombocytopenia | | | | |
ChiCTR2200064890: Efficacy and Safety of Avatrombopag in Patients with Thrombocytopenia of Ovarian Cancer Treated with Niraparib |
|
|
| Not yet recruiting | N/A | 67 | | Avatrombopag | Peking Union Medical College Hospital; Peking Union Medical College Hospital, Self selected topic: Efficacy and Safety of Avatrombopag in Patients with Thrombocytopenia of Ovarian Cancer Treated with Niraparib(SKX-CIT-2210) | Thrombocytopenia in patients with ovarian cancer | | | | |
ChiCTR2400086350: A Randomized, Double-Blind, Placebo-Controlled Study of the Combination of Spleen-Invigorating Kidney-Nourishing Fire-Purging Formula and TPO-RA for the Treatment of Primary Immune Thrombocytopenia After First-Line Treatment Failure |
|
|
| Not yet recruiting | N/A | 78 | | TPO-RA (avatrombopag dose of 5 mg, orally once daily) + Placebo (As the placebo needs to be identical to the tested Chinese medicine in appearance, color, smell, taste, packaging, usage, and dosage, the placebo will be made using one-tenth of the dose of the Chinese medicinal herbs from the spleen-tonifying, kidney-nourishing, and fire-purging formula. It will be prepared as Chinese herbal granules by our hospital's Chinese medicine preparation center. According to the regulations of the Chinese Pharmacopoeia, no additives will be used. It will be vacuum-packed, with one packet taken twice daily, to be consumed half an hour after breakfast and dinner.); TPO-RA (avatrombopag dose of 5 mg, orally once daily) + Spleen-tonifying, Kidney-nourishing, and Fire-purging Formula(Composition of the Spleen-tonifying, Kidney-nourishing, and Fire-purging Formula: Astragalus membranaceus 24g, Codonopsis pilosula 15g, Atractylodes macrocephala 12g, Processed Ligustrum lucidum 20g, Rehmannia glutinosa 15g, Cuscuta chinensis 15g, Paeonia suffruticosa 15g, Agrimonia pilosa 15g, Selaginella tamariscina 15g, and Prepared Glycyrrhiza uralensis 6g, totaling 10 ingredients.The above prescription will be prepared as Chinese herbal granules by our hospital's Chinese medicine preparation center. According to the regulations of the Chinese Pharmacopoeia, no additives will be used. It will be vacuum-packed, with one packet taken twice daily, to be consumed half an hour after breakfast and dinner.) | Shanghai Municipal Hospital of Traditional Chinese Medicine; Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai Municipal Science and Technology Commission | Immune Thrombocytopenia | | | | |
ADOPT, NCT04943042: An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP |
|
|
| Active, not recruiting | N/A | 150 | Europe, RoW | Avatrombopag, Doptelet® | Swedish Orphan Biovitrum | Immune Thrombocytopenia, ITP | 05/25 | 05/25 | | |
NCT05518331: The Safety and Efficacy Study of Avatrombopag Switch in TPO-RA Refractory AA |
|
|
| Recruiting | N/A | 39 | RoW | avatrombopag, CSA | Institute of Hematology & Blood Diseases Hospital, Peking University People's Hospital, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Second Hospital of Shanxi Medical University, First Affiliated Hospital of Harbin Medical University, The First Hospital of Hebei Medical University | Refractory Aplastic Anemia | 06/25 | 01/26 | | |
NCT04949009: Avatrombopag in the Treatment of Primary Immune Thrombocytopenia(ITP) |
|
|
| Recruiting | N/A | 400 | RoW | Avatrombopag, Doptelet | Shandong University | Primary Immune Thrombocytopenia | 10/21 | 03/22 | | |
NCT05087459: Treatment of Avatrombopag for Thrombocytopenia in Patients Undergoing Selective Resection of Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 141 | RoW | Avatrombopag, Doptelet | Shanghai Zhongshan Hospital | Thrombocytopenia | 06/22 | 07/22 | | |
NCT04913597: A Study of Switching Avatrombopag and Rh-TPO in ITP |
|
|
| Not yet recruiting | N/A | 100 | NA | | Peking University People's Hospital | Corticosteroid-resistant or Relapsed ITP | 12/22 | 12/23 | | |
